Literature DB >> 8370690

Defects in the HSD11 gene encoding 11 beta-hydroxysteroid dehydrogenase are not found in patients with apparent mineralocorticoid excess or 11-oxoreductase deficiency.

H Nikkilä1, G M Tannin, M I New, N F Taylor, G Kalaitzoglou, C Monder, P C White.   

Abstract

The syndrome of apparent mineralocorticoid excess (AME) is a form of low renin hypertension that is thought to be caused by congenital deficiency of 11 beta-hydroxysteroid dehydrogenase (11HSD) activity. This enzyme converts cortisol to cortisone and apparently prevents cortisol from acting as a ligand for the mineralocorticoid (type I) receptor. It also catalyzes the reverse oxoreductase (cortisone to cortisol) reaction. Four patients with AME and the parents of the first patient described (now decreased) were analyzed for mutations in the cloned HSD11 gene encoding an 11HSD enzyme. A patient with suspected cortisone reductase deficiency was also studied. No gross deletions or rearrangements in the HSD11 gene were apparent on hybridizations of blots of genomic DNA. Direct sequencing of polymerase chain reaction-amplified fragments corresponding to the coding sequences, intronexon junctions, and proximal untranslated regions of this gene revealed no mutations. AME may involve mutations in a gene for another enzyme with 11HSD activity or perhaps another cortisol-metabolizing enzyme.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8370690     DOI: 10.1210/jcem.77.3.8370690

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  12 in total

Review 1.  Apparent mineralocorticoid excess syndromes.

Authors:  M Shimojo; P M Stewart
Journal:  J Endocrinol Invest       Date:  1995 Jul-Aug       Impact factor: 4.256

Review 2.  Defects of steroidogenesis.

Authors:  A Biason-Lauber; M Boscaro; F Mantero; G Balercia
Journal:  J Endocrinol Invest       Date:  2010-02-24       Impact factor: 4.256

3.  Mutations of the hexose-6-phosphate dehydrogenase gene rarely cause hyperandrogenemic polycystic ovary syndrome.

Authors:  Kenan Qin; Robert L Rosenfield
Journal:  Steroids       Date:  2010-11-02       Impact factor: 2.668

4.  Steroid disorders in children: congenital adrenal hyperplasia and apparent mineralocorticoid excess.

Authors:  M I New; R C Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-26       Impact factor: 11.205

Review 5.  Hexose 6-phosphate dehydrogenase (H6PD) and corticosteroid metabolism.

Authors:  Perrin C White; Daniela Rogoff; D Randy McMillan; Gareth G Lavery
Journal:  Mol Cell Endocrinol       Date:  2007-01-19       Impact factor: 4.102

6.  Congenital deficiency of 11beta-hydroxysteroid dehydrogenase (apparent mineralocorticoid excess syndrome): diagnostic value of urinary free cortisol and cortisone.

Authors:  M Palermo; G Delitala; F Mantero; P M Stewart; C H Shackleton
Journal:  J Endocrinol Invest       Date:  2001-01       Impact factor: 4.256

7.  Urinary cortisol metabolites in the assessment of peripheral thyroid hormone action: overt and subclinical hypothyroidism.

Authors:  M C Vantyghem; A Ghulam; C Hober; C Schoonberg; M D'Herbomez; A Racadot; A Boersma; J Lefebvre
Journal:  J Endocrinol Invest       Date:  1998-04       Impact factor: 4.256

Review 8.  A genetic defect resulting in mild low-renin hypertension.

Authors:  R C Wilson; S Dave-Sharma; J Q Wei; V R Obeyesekere; K Li; P Ferrari; Z S Krozowski; C H Shackleton; L Bradlow; T Wiens; M I New
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-18       Impact factor: 11.205

9.  Molecular basis for hypertension in the "type II variant" of apparent mineralocorticoid excess.

Authors:  A Li; R Tedde; Z S Krozowski; A Pala; K X Li; C H Shackleton; F Mantero; M Palermo; P M Stewart
Journal:  Am J Hum Genet       Date:  1998-08       Impact factor: 11.025

10.  Purification of 11 beta-hydroxysteroid dehydrogenase type 2 from human placenta utilizing a novel affinity labelling technique.

Authors:  R W Brown; K E Chapman; P Murad; C R Edwards; J R Seckl
Journal:  Biochem J       Date:  1996-02-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.